2016 russell ross memorial lecture in vascular biology: Molecular-cellular mechanisms in the progression of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 2, 2017, Pages 183-189

  Tabas, Ira ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

apoptosis; atherosclerosis; efferocytosis; inflammation; macrophages; necrosis; resolution

Indexed keywords

APOPTOSIS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; EFFEROCYTOSIS; HEART INFARCTION; HUMAN; NECROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUDDEN CARDIAC DEATH; TISSUE INJURY; UNSTABLE ANGINA PECTORIS; VASCULAR BIOLOGY; ANIMAL; ARTERY; ATHEROSCLEROTIC PLAQUE; DISEASE EXACERBATION; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

APOLIPOPROTEIN B; AUTACOID;

ANIMALS; APOLIPOPROTEINS B; APOPTOSIS; ARTERIES; ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NECROSIS; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 85011026182     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308036     Document Type: Review

References (99)

1. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
2. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844. doi: 10.1161/ CIRCULATIONAHA.106.676890.
3. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 1986;314:488-500. doi: 10.1056/NEJM198602203140806.
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126. doi: 10.1056/NEJM199901143400207.
5. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051. doi: 10.1161/ATVBAHA.108.179705.
6. Hansson GK, Zhou X, Törnquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann N Y Acad Sci. 2000;902:53-62; discussion 62.
7. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7(suppl 1):332-339. doi: 10.1111/j.1538-7836.2009.03404.x.
8. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi: 10.1016/j. ahj.2011.06.012.
9. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4:a006049.
10. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis. Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007;27:1159-1165.
11. Skalén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754. doi: 10.1038/ nature00804.
12. Brito V, Mellal K, Portelance SG, Pérez A, Soto Y, deBlois D, Ong H, Marleau S, Vázquez AM. Induction of anti-anti-idiotype antibodies against sulfated glycosaminoglycans reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32:2847-2854. doi: 10.1161/ATVBAHA.112.300444.
13. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
14. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148:1242-1257. doi: 10.1016/j.cell.2012.03.001.
15. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
16. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specific epitopes are dangerassociated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108:235-248. doi: 10.1161/ CIRCRESAHA.110.223875.
17. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002;110:905-911. doi: 10.1172/JCI16452.
18. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361. doi: 10.1038/nature08938.
19. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med. 2001;11:142-147.
20. Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K, Asada Y, Okada K, Ishibashi-Ueda H, Gabbiani G, Bochaton-Piallat ML, Mochizuki N, Kitakaze M. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 2007;116:1226-1233. doi: 10.1161/CIRCULATIONAHA.106.682054.
21. Schwartz EA, Reaven PD. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta. 2012;1821:858-866. doi: 10.1016/j.bbalip.2011.09.021.
22. Bismuth J, Lin P, Yao Q, Chen C. Ceramide: a common pathway for atherosclerosis? Atherosclerosis. 2008;196:497-504. doi: 10.1016/j. atherosclerosis.2007.09.018.
23. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost. 2011;106:779-786. doi: 10.1160/TH11-05-0321.
24. Gimbrone MA Jr, García-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol. 2013;22:9-15. doi: 10.1016/j.carpath.2012.06.006.
25. Conway DE, Schwartz MA. Flow-dependent cellular mechanotransduction in atherosclerosis. J Cell Sci. 2013;126(pt 22):5101-5109. doi: 10.1242/jcs.138313.
26. Pavlides S, Gutierrez-Pajares JL, Iturrieta J, Lisanti MP, Frank PG. Endothelial caveolin-1 plays a major role in the development of atherosclerosis. Cell Tissue Res. 2014;356:147-157. doi: 10.1007/s00441-013-1767-7.
27. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA. 2000;97:9052-9057.
28. McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, Hayat SA. The changing face of cardiovascular disease 2000-2012: an analysis of the world health organisation global health estimates data. Int J Cardiol. 2016;224:256-264. doi: 10.1016/j.ijcard.2016.09.026.
29. Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ. Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opin Pharmacother. 2015;16:347-356. doi: 10.1517/14656566.2014.986094.
30. Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/ kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36:2415-2424. doi: 10.1093/eurheartj/ehv174.
31. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575-585. doi: 10.1016/j.cmet.2011.07.015.
32. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766-781. doi: 10.1016/S0140-6736(14)60460-8.
33. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241. doi: 10.1038/35025203.
34. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503-516.
35. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013. doi: 10.1056/ NEJMra1216063.
36. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212. doi: 10.1038/ni.2001.
37. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355. doi: 10.1016/j.cell.2011.04.005.
38. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709-721. doi: 10.1038/ nri3520.
39. Koltsova EK, Hedrick CC, Ley K. Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr Opin Lipidol. 2013;24:371-380. doi: 10.1097/MOL.0b013e328363d298.
40. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422. doi: 10.1038/nm.2538.
41. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-918.
42. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375. doi: 10.1056/ NEJM198705283162204.
43. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002;15:439-446.
44. Libby P, Pasterkamp G. Requiem for the 'vulnerable plaque'. Eur Heart J. 2015;36:2984-2987. doi: 10.1093/eurheartj/ehv349.
45. Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. 2015;36:1394-1404. doi: 10.1093/eurheartj/ehv044.
46. Ball RY, Stowers EC, Burton JH, Cary NR, Skepper JN, Mitchinson MJ. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis. 1995;114:45-54.
47. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009;50(suppl):S382-S387. doi: 10.1194/jlr.R800032-JLR200.
48. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264. doi: 10.1161/01.ATV.0000184783.04864.9f.
49. Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 2013;3:200-210. doi: 10.1016/j. celrep.2012.12.012.
50. Meng L, Jin W, Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci USA. 2015;112:11007-11012. doi: 10.1073/pnas.1514730112.
51. Karunakaran D, Geoffrion M, Wei L, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016;2:e1600224. doi: 10.1126/sciadv.1600224.
52. Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, D'Herde K, Vandenabeele P. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ. 2006;13:2011-2022. doi: 10.1038/sj.cdd.4401900.
53. Newby AC. Proteinases and plaque rupture: unblocking the road to translation. Curr Opin Lipidol. 2014;25:358-366. doi: 10.1097/ MOL.0000000000000111.
54. Ohayon J, Finet G, Gharib AM, Herzka DA, Tracqui P, Heroux J, Rioufol G, Kotys MS, Elagha A, Pettigrew RI. Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture. Am J Physiol Heart Circ Physiol. 2008;295:H717-H727. doi: 10.1152/ajpheart.00005.2008.
55. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325-332. doi: 10.1096/ fj.06-7227rev.
56. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-882. doi: 10.1016/j.cell.2010.02.029.
57. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010;177:1576-1591. doi: 10.2353/ajpath.2010.100322.
58. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62-70. doi: 10.1038/nri2470.
59. Wallace JL, Ianaro A, Flannigan KL, Cirino G. Gaseous mediators in resolution of inflammation. Semin Immunol. 2015;27:227-233. doi: 10.1016/j. smim.2015.05.004.
60. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339:166-172. doi: 10.1126/ science.1230720.
61. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22:3595-3606. doi: 10.1096/ fj.08-112201.
62. Merched AJ, Serhan CN, Chan L. Nutrigenetic disruption of inflammationresolution homeostasis and atherogenesis. J Nutrigenet Nutrigenomics. 2011;4:12-24. doi: 10.1159/000326890.
63. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36-46. doi: 10.1038/nri2675.
64. Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I. An imbalance between specialized pro-resolving lipid mediators and proinflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun. 2016;7:12859. doi: 10.1038/ncomms12859.
65. Viola JR, Lemnitzer P, Jansen Y, Csaba G, Winter C, Neideck C, Silvestre-Roig C, Dittmar G, Döring Y, Drechsler M, Weber C, Zimmer R, Cenac N, Soehnlein O. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res. 2016;119:1030-1038. doi: 10.1161/ CIRCRESAHA.116.309492.
66. Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, Kuriakose G, Perretti M, Farokhzad O, Farokzhad O, Tabas I. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med. 2015;7:275ra20. doi: 10.1126/scitranslmed.aaa1065.
67. Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci USA. 2014;111:14530-14535. doi: 10.1073/pnas.1410851111.
68. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol. 1995;147:251-266.
69. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1256-1261. doi: 10.1161/01.ATV.0000166517.18801.a7.
70. Schrijvers DM, De Meyer GR, Herman AG, Martinet W. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res. 2007;73:470-480. doi: 10.1016/j. cardiores.2006.09.005.
71. Van Vré EA, Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:887-893. doi: 10.1161/ATVBAHA.111.224873.
72. Otsuka F, Kramer MC, Woudstra P, Yahagi K, Ladich E, Finn AV, de Winter RJ, Kolodgie FD, Wight TN, Davis HR, Joner M, Virmani R. Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: a pathology study. Atherosclerosis. 2015;241:772-782. doi: 10.1016/j.atherosclerosis.2015.05.011.
73. Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16:907-917. doi: 10.1038/ni.3253.
74. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol. 2001;11:R795-R805.
75. Camenisch TD, Koller BH, Earp HS, Matsushima GK. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol. 1999;162:3498-3503.
76. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK, Tabas I. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem. 2006;281:6707-6717. doi: 10.1074/jbc. M510579200.
77. Tabas I. Apoptosis and efferocytosis in mouse models of atherosclerosis. Curr Drug Targets. 2007;8:1288-1296.
78. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol. 2008;28:1421-1428. doi: 10.1161/ ATVBAHA.108.167197.
79. Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, Fazio S. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol. 2010;30:787-795. doi: 10.1161/ATVBAHA.109.202051.
80. Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, Fazio S, Linton MF. Macrophage SR-BI mediates efferocytosis via Src/PI3K/ Rac1 signaling and reduces atherosclerotic lesion necrosis. J Lipid Res. 2015;56:1449-1460. doi: 10.1194/jlr.M056689.
81. Ait-Oufella H, Pouresmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R, Offenstadt G, Lesèche G, Cohen PL, Tedgui A, Mallat Z. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1429-1431. doi: 10.1161/ ATVBAHA.108.169078.
82. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005;1:201-213. doi: 10.1016/j.cmet.2005.02.002.
83. Vengrenyuk Y, Nishi H, Long X, et al. Cholesterol loading reprograms the miR-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol. 2015:35;535-546.
84. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
85. Cui D, Thorp E, Li Y, Wang N, Yvan-Charvet L, Tall AR, Tabas I. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol. 2007;82:1040-1050. doi: 10.1189/jlb.0307192.
86. Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86-90. doi: 10.1038/nature18935.
87. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109:1026-1033. doi: 10.1182/blood-2006-05-021634.
88. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 2011;286:33335-33344. doi: 10.1074/jbc.M111.263020.
89. Garbin U, Baggio E, Stranieri C, Pasini A, Manfro S, Mozzini C, Vallerio P, Lipari G, Merigo F, Guidi G, Cominacini L, Fratta Pasini A. Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids? Cardiovasc Res. 2013;97:125-133. doi: 10.1093/cvr/cvs301.
90. Cai B, Thorp EB, Doran AC, et al. MerTK cleavage promotes plaque necrosis and defective resolution in advanced atherosclerosis. J Clin Invest. In press. doi: 10.1172/JCI90520.
91. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M, Winkler JW, Petasis NA. Novel proresolving aspirintriggered DHA pathway. Chem Biol. 2011;18:976-987. doi: 10.1016/j. chembiol.2011.06.008.
92. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874. doi: 10.1038/nature05877.
93. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem. 2006;281:38376-38384.
94. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120:e60-e72. doi: 10.1182/blood-2012-04-423525.
95. Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G, Tabas I. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci USA. 2016;113:6526-6531. doi: 10.1073/pnas.1524292113.
96. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptordependent actions. Arterioscler Thromb Vasc Biol. 2012;32:1970-1978. doi: 10.1161/ATVBAHA.112.249508.
97. Fisher EA. Regression of atherosclerosis: the journey from the liver to the plaque and back. Arterioscler Thromb Vasc Biol. 2016;36:226-235. doi: 10.1161/ATVBAHA.115.301926.
98. Brown MS, Goldstein JL. Heart attacks: gone with the century? Science. 1996;272:629.
99. Grootaert MO, Schrijvers DM, Van Spaendonk H, Breynaert A, Hermans N, Van Hoof VO, Takahashi N, Vandenabeele P, Kim SH, De Meyer GR, Martinet W. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis. 2016;252:166-174. doi: 10.1016/j.atherosclerosis.2016.06.045.